Lazertinib

• Description:

  Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer[1].

• Product Name Alternative:

  YH25448; GNS-1480

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• Target:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Lazertinib.html

• Purity:

  99.87

• Solubility:

  DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O

• Molecular Formula:

  C30H34N8O3

• Molecular Weight:

  554.64

• Precautions:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• References & Citations:

  [1]Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  EGFR/ErbB1/HER1

• CAS Number:

  [1903008-80-9]